A rational strategy for a malarial vaccine development

Microbes and Infection

Volumn 9, Issue 6, 2007, Pages 751-760

  Lozano, José Manuel ^a,b   Patarroyo, Manuel Elkin ^a,b  

^a FUNDACIÓN INSTITUTO DE INMUNOLOGÍA DE COLOMBIA FIDIC   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Anti malarial vaccine; MHC II peptide TCR complex; Peptide bond isoster; Three dimensional probe

Indexed keywords

9B ANTIGEN; ANTIVIRUS AGENT; CANCER VACCINE; CD8 ANTIGEN; GLUCOSYLTRANSFERASE; HB 19; HB 19A; HIGH ACTIVITY BINDING PEPTIDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LUTEINIZING HORMONE RELEASING HORMONE VACCINE; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B4; PEPTIDE 24112; PROTEIN VP1; SCHISTOSOMIASIS VACCINE; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; TUMOR VACCINE; UNCLASSIFIED DRUG; VACCINE;

CANCER; DENTAL CARIES; DRUG BINDING; DRUG MECHANISM; DRUG SYNTHESIS; FOOT AND MOUTH DISEASE; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MALARIA; MOLECULAR INTERACTION; NONHUMAN; PARASITE IMMUNITY; PRIORITY JOURNAL; PROTEIN BINDING; SHORT SURVEY; THREE DIMENSIONAL IMAGING; TUMOR;

ANIMALS; DRUG DESIGN; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALARIA; MALARIA VACCINES; MODELS, MOLECULAR; PEPTIDES; PLASMODIUM; PROTOZOAN PROTEINS; RECEPTORS, ANTIGEN, T-CELL; VACCINES, SYNTHETIC;

EID: 34247480023     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2007.02.004     Document Type: Short Survey

References (70)

1. Greten T.F., and Jaffee E.M. Cancer vaccines. J. Clin. Oncol. 17 (1999) 1047-1060
2. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., and Levitsky H. The central role of CD4(+) T-cells in the antitumor immune response. J. Exp. Med. 21 (1998) 2357-2368
3. Qin Z., Richter G., Schuler T., Ibe S., Cao X., and Blankenstein T. B cells inhibit induction of T-cell-dependent tumor immunity. Nat. Med. 4 (1998) 627-630
4. Pardoll D.M. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2 (2002) 227-238
5. Stern L.J., and Wiley D.C. Antigenic peptide binding by class I and class II histocompatibility proteins. Structure 2 (1994) 245-251
6. Rammensee H.G., Friede T., and Stevanovíc S. MHC ligands and peptide motifs: first listing. Immunogenetics 41 (1995) 178-228
7. Berzofsky J.A., Terabe M., Oh S., Belyakov I.M., Ahlers J.D., Janik J.E., and Morris J.C. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113 (2004) 1515-1525
8. Jones T.R., and Hoffman S.L. Malaria vaccine development. Clin. Microbiol. Rev. 7 (1994) 303-310
9. Taboga O., Tami C., Carrillo E., Nunez J.I., Rodriguez A., Saiz J.C., Blanco E., Valero M.L., Roig X., Camarero J.A., Andreu D., Mateu M.G., Giralt E., Domingo E., Sobrino F., and Palma E.L. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J. Virol. 71 (1997) 2606-2614
10. Parmiani G., Castelli C., Dalerba P., Mortarini R., Rivoltini L., Marincola F.M., and Anichini A. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. J. Natl. Cancer. Inst. 5 (2002) 805-818
11. Melief C., Offringa J.R., Toes R.E., and Kast W.M. Peptide-based cancer vaccines. Curr. Opin. Immunol. 8 (1996) 651
12. Lu J., Higashimoto Y., Appella E., and Celis E. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J. Immunol. 172 (2004) 4575-4582
13. Keding S.J., and Danishefsky S.J. Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 11937-11942
14. Nisole S., Said E.A., Mische C., Prevost M.C., Krust B., Bouvet P., Bianco A., Briand J.P., and Hovanessian A.G. The anti-HIV pentameric pseudopeptide HB-19 binds the C-terminal end of nucleolin and prevents anchorage of virus particles in the plasma membrane of target T-cells. Biol. Chem. 277 (2002) 20877-20886
15. Wang C.Y., Shen M., Tam G., Fang X.D., Ye J., Shen F., Walfield A.M., Wang J.J., Li M.L., Li X.M., Salas M., Shearer M.H., Kennedy R.C., and Hanson C.V. Synthetic AIDS vaccine by targeting HIV receptor. Vaccine 21 (2002) 89-97
16. Tarrab-Hazdai R., Schechtman D., and Arnon R. Synthesis and characterization of a protective peptide-based vaccine against Schistosoma mansoni. Infect. Immun. 66 (1998) 4526-4530
17. Smith D.J., Taubman M.A., and Ebersole J.L. Effect of oral administration of glucosyltransferase antigens on experimental dental caries. Infect. Immun. 26 (1979) 81-89
18. Smith D.J., King W.F., Barnes L.A., Trantolo D., Wise D.L., and Taubman M.A. Facilitated intranasal induction of mucosal and systemic immunity to mutans streptococcal glucosyltransferase peptide vaccines. Infect. Immun. 69 (2001) 4767-4773
19. Ogasawara K., Naruse H., Itoh Y., Gotohda T., Arikawa J., Kida H., Good R.A., and Onoe K. A strategy for making synthetic peptide vaccines. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 8995-8999
20. Blaney J.E., Nobusawa E., Brehm M.A., Bonneau R.H., Mylin L.M., Fu T.M., Kawoaka Y., and Tevethia S.S. Immunization with a single major histocompatibility class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J. Virol. 72 (1998) 9567-9574
21. Mester J.C., Highlander S.L., Osmand A.P., Glorioso J.C., and Rouse B.T. Herpes simplex virus type 1-specific immunity induced by peptides corresponding to an antigenic site of glyoprotein B. J. Virol. 64 (1990) 5277-5283
22. Rosenthal K.S., Mao M., Horne W.I., Wright C., and Zimmerman D. Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Vaccine 17 (1999) 535-542
23. Kumaraguru U., Gierynska M., Norman S., Bruce B.D., and Rouse B.T. Immunization with chaperone-peptide complex includes low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection. J. Virol. 76 (2002) 136-141
24. Yu Z., Karem K.L., Kanangat S., Manickan E., and Rouse B.T. Protection by minigenes: a novel approach of DNA vaccines. Vaccine 16 (1998) 1660-1667
25. Zheng B., Graham F.L., Johnson D.J., Hanke T., McDermott M.R., and Prevec L. Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. Vaccine 11 (1993) 1191-1198
26. Chabalgoity J.A., Khan C.M., Nash A.A., and Hormaeche C.E. A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Mol. Microbiol. 19 (1996) 791-801
27. Tigges M.A., Leng S., Johnson D.C., and Burke R.L. Human herpes simplex (HSV)-specific CD8-CTL clones recognize HSV-2-infected fibroblasts after treatment with IFN-gamma or when virion host shutoff functions are disabled. J. Immunol. 156 (1996) 3901-3910
28. Ghosh S., and Jackson D.C. Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines. Int. Immunol. 11 (1999) 1103-1110
29. Brown F. New approaches to vaccination against foot-and-mouth disease. Vaccine 10 (1992) 1022-1026
30. Bittle J.L., Houghten R.A., Alexander H., Shinnick T.M., Sutcliffe J.G., Lerner R.A., Rowlands D.J., and Brown F. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature 298 (1982) 30-33
31. Francis M.J., Hastings G.Z., Brown F., McDermed J., Lu Y.A., and Tam J.P. Immunological evaluation of the multiple antigen peptide (MAP) system using the major immunogenic site of foot-and-mouth disease virus. Immunology 73 (1991) 249-254
32. Briand J.P., Benkirane N., Guichard G., Newman J.F., van Regenmortel M.H., Brown F., and Muller S. A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long-lasting protective neutralizing antibodies. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 12545-12550
33. Patarroyo M.E., Romero P., Torres M.L., Clavijo P., Moreno A., Martinez A., Rodriguez R., Guzman F., and Cabezas E. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 328 (1987) 629-632
34. Patarroyo M.E., Amador R., Clavijo P., Moreno A., Guzman F., Romero P., Tascon R., Franco A., Murillo L.A., and Ponton G. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332 (1988) 158-161
35. Graves P., and Gelband H. Vaccines for preventing malaria. Cochrane Database Syst. Rev. 2 (2000) CD000129
36. Valero M.V., Amador R., Aponte J.J., Narvaez A., Galindo C., Silva Y., Rosas J., Guzman F., and Patarroyo M.E. Evaluation of SPf66 malaria vaccine during a 22-month follow-up field trial in the Pacific coast of Colombia. Vaccine 14 (1996) 1466-1470
37. Graves P., Gelband H., and Garner P. The SPf66 malaria vaccine: what is the evidence for efficacy?. Parasitol. Today 14 (1998) 218-220
38. Cubillos M., Salazar L.M., Torres L., and Patarroyo M.E. Protection against experimental P. falciparum malaria is associated with short AMA-1 peptide analogue alpha-helical structures. Biochimie 84 (2002) 1181-1188
39. Cubillos M., Espejo F., Purmova J., Martinez J.C., and Patarroyo M.E. Alpha helix shortening in 1522 MSP-1 conserved peptide analogs is associated with immunogenicity and protection against P. falciparum malaria. Proteins 50 (2003) 400-409
40. Cifuentes G., Patarroyo M.E., Urquiza M., Ramirez L.E., Reyes C., and Rodriguez R. Distorting malaria peptide backbone structure to enable fitting into MHC class II molecules renders modified peptides immunogenic and protective. J. Med. Chem. 46 (2003) 2250-2253
41. Bermudez A., Cifuentes G., Guzman F., Salazar L.M., and Patarroyo M.E. Immunogenicity and protectivity of Plasmodium falciparum EBA-175 peptide and its analog is associated with alpha-helical region shortening and displacement. Biol. Chem. 384 (2003) 1443-1450
42. Torres M.H., Salazar L.M., Vanegas M., Guzman F., Rodriguez R., Silva Y., Rosas J., and Patarroyo M.E. Modified merozoite surface protein-1 peptides with short alpha helical regions are associated with inducing protection against malaria. Eur. J. Biochem. 270 (2003) 3946-3952
43. Cifuentes G., Guzman F., Alba M.P., Salazar L.M., and Patarroyo M.E. Analysis of a Plasmodium falciparum EBA-175 peptide with high binding capacity to erythrocytes and their analogues using 1H NMR.J. Struct. Biol. 141 (2003) 115-121
44. Salazar L.M., Alba M.P., Torres M.H., Pinto M., Cortes X., Torres L., and Patarroyo M.E. Protection against experimental malaria associated with AMA-1 peptide analogue structures. FEBS Lett. 527 (2002) 95-100
45. Guzman F., Jaramillo K., Salazar L.M., Torres A., Rivera A., and Patarroyo M.E. 1H-NMR structures of the Plasmodium falciparum 1758 erythrocyte binding peptide analogues and protection against malaria. Life Sci. 71 (2002) 2773-2785
46. Patarroyo M.E., Cifuentes G., Salazar L.M., Espejo F., Alba M.P., and Bermudez A. Based on HLA-DR beta1* allele binding specificities, striking differences in distance and TCR contacting residue orientation can be observed in modified protection-inducing malarial synthetic peptides. Curr. Med. Chem. 12 (2005) 2849-2865
47. Patarroyo M.E., Alba M.P., Vargas L.E., Silva Y., Rosas J., and Rodriguez R. Peptides inducing short-lived antibody responses against Plasmodium falciparum malaria have shorter structures and are read in a different MHC II functional register. Biochemistry 44 (2005) 6745-6754
48. Patarroyo M.E., Salazar L.M., Cifuentes G., Lozano J.M., Delgado G., Rivera Z., Rosas J., and Vargas L.E. Protective cellular immunity against P. falciparum malaria merozoites is associated with a different P7 and P8 residue orientation in the MHC-peptide-TCR complex. Biochimie. 88 (2006) 219-230
49. Espejo F., Cubillos M., Salazar L.M., Guzman F., Urquiza M., Ocampo M., Silva Y., Rodriguez R., Lioy E., and Patarroyo M.E. Structure, immunogenicity, and protectivity relationship for the 1585 malarial peptide and its substitution analogues. Angew. Chem. Int. Ed. Engl. 40 (2001) 4654-4657
50. Tolia N.H., Enemark E.J., Sim B.K., and Joshua-Tor L. Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum. Cell 122 2 (2005 Jul 29) 183-193 Erratum in: Cell 122 (2005) 485
51. Feng Z.P., Keizer D.W., Stevenson R.A., Yao S., Babon J.J., Murphy V.J., Anders R.F., and Norton R.S. Structure and inter-domain interactions of domain II from the blood-stage malarial protein, apical membrane antigen 1. J. Mol. Biol. 350 (2005) 641-656
52. Pizarro J.C., Chitarra V., Verger D., Holm I., Petres S., Dartevelle S., Nato F., Longacre S., and Bentley G.A. Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate. J. Mol. Biol. 328 (2003) 1091-1103
53. Bjorkman P.J., Saper M.A., Samraoui B., Bennett W.S., Strominger J.L., and Wiley D.C. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329 (1987) 506-512
54. Stern L.J., Brown J.H., Jardetzky T.S., Gorga J.C., Urban R.G., Strominger J.L., and Wiley D.C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368 6468 (1994) 215-221
55. Hare B.J., Wyss D.F., Osburne M.S., Kern P.S., Reinherz E.L., and Wagner G. Structure, specificity and CDR mobility of a class II restricted single-chain T-cell receptor. Nat. Struct. Biol. 6 (1999) 574-581
56. Garcia K.C., Degano M., Stanfield R.L., Brunmark A., Jackson M.R., Peterson P.A., Teyton L., and Wilson I.A. An alphabeta T-cell receptor structure at 2,5 A and its orientation in the TCR-MHC complex. Science 274 (1996) 209-219
57. Reinherz E.L., Tan K., Tang L., Kern P., Liu J., Xiong Y., Hussey R.E., Smolyar A., Hare B., Zhang R., Joachimiak A., Chang H.C., Wagner G., and Wang J. The crystal structure of a T-cell receptor in complex with peptide and MHC class II. Science 286 (1999) 1913-1921
58. Murillo L.A., Rocha C.L., Mora A.L., Kalil J., Goldenberg A.K., and Patarroyo M.E. Molecular analysis of HLA DR4-beta 1 gene in malaria vaccines, typing and subtyping by PCR technique and oligonucleotides. Parasite Immunol. 13 (1991) 201-210
59. Vargas L.E., Parra C.A., Salazar L.M., Guzman F., Pinto M., and Patarroyo M.E. MHC allele-specific binding of a malaria peptide makes it become promiscuous on fitting a glycine residue into pocket 6. Biochem. Biophys. Res. Commun. 307 (2003) 148-156
60. Suárez C.F., Trujillo E., Estupiñán M., Baquero J., Parry-López C.A., Rodríguez R., and Patarroyo M.E. Owl monkey MHC-DRB exon 2 reveals high similarity with several HLA-DRB lineages. Immunogenetics 58 (2006) 542-558
61. Moncada C.A., Guerrero E., Cardenas P., Suarez C.F., Patarroyo M.E., and Patarroyo M.A. The T-cell receptor in primates: identifying and sequencing new owl monkey TRBV gene sub-groups. Immunogenetics 57 (2005) 42-52
62. Hernández E., Suárez C.F., Parra-López C.A., Patarroyo M.A., and Patarroyo M.E. Identification of five different IGHV gene families in owl monkeys (Aotus nancymaae). Tissue Antigens 6 (2005) 640-649
63. Espejo F., Bermudez A., Torres E., Urquiza M., Rodriguez R., Lopez Y., and Patarroyo M.E. Shortening and modifying the 1513 MSP-1 peptide's alpha-helical region induces protection against malaria. Biochem. Biophys. Res. Commun. 315 (2004) 418-427
64. Spatola A. Chemistry and biochemistry of amino acids. In: Weinstein B. (Ed). Peptides and Proteins vol. 7 (1993), Marcel Dekker, New York 267-357
65. Lozano J.M., Salazar L.M., Rivera Z., and Patarroyo M.E. What is hidden behind peptide bond restriction and carbon asymmetry of conserved antigens? Peptide bond isosters and chirally transformed pseudopeptides as novel elements for synthetic vaccines and therapeutic agents against malaria. Curr. Org. Chem. 10 4 (2006) 433-456
66. Bastian M., Lozano J.M., Patarroyo M.E., Pluschke G., and Daubenberger C.A. Characterization of a reduced peptide bond analogue of a promiscuous CD4 T-cell epitope derived from the Plasmodium falciparum malaria vaccine candidate merozoite surface protein 1. Mol. Immunol. 41 (2004) 775-784
67. Lozano J.M., Alba M.P., Vanegas M., Silva Y., Torres-Castellanos J.L., and Patarroyo M.E. MSP-1 malaria pseudopeptide analogs: biological and immunological significance and three-dimensional structure. Biol. Chem. 384 (2003) 71-82
68. Lozano J.M., Espejo F., Vera R., Vargas L.E., Rosas J., Lesmes L., Torres E., Cortes J., Silva Y., and Patarroyo M.E. Protection against malaria induced by chirally modified Plasmodium falciparum's MSP-142 pseudopeptides. Biochem. Biophys. Res. Commun. 329 (2005) 1053-1066
69. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., Ballou W.R., Conway D.J., Reece W.H., Gothard P., Yamuah L., Delchambre M., Voss G., Greenwood B.M., Hill A., McAdam K.P., Tornieporth N., Cohen J.D., and Doherty T. RTS.S Malaria Vaccine Trial Team. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (2001) 1927-1934
70. Moore A.C., and Hill A.V. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol. Rev. 199 (2004) 126-143